Tag: NHEJ

C698R mutation in Lrsam1 gene impairs nerve regeneration in a CMT2P mouse model

Animal generation The Lrsam1C698R knock-in mice were generated on a C57Bl/6J background using the CRISPR/Cas9 technique. Briefly, single-cell zygotes from C57BL/6J mice were microinjected with mRNA encoding Cas9 and a guide sequence (5′-ACAGCAGCAGACGTGGCCAC-3′ at 20 ng/µl) to target the exon 26 of Lrsam1. A single stranded DNA oligo carrying the C698R mutation…

Continue Reading C698R mutation in Lrsam1 gene impairs nerve regeneration in a CMT2P mouse model

CRISPR Gene Detection and Diagnostic Industry 2022 Market Size, Share and Growth, Global Segments Analysis and Dynamic Research Report 2029

The Wide Ranging CRISPR Gene Detection and Diagnostic Business Report encompasses a thorough study of current situation of the global market along with several market dynamics. The market research report is a demonstrated source of information which offers a telescopic view of the current market trends, size, share, growth, demand,…

Continue Reading CRISPR Gene Detection and Diagnostic Industry 2022 Market Size, Share and Growth, Global Segments Analysis and Dynamic Research Report 2029

Sigma-Aldrich Files Substantive Preliminary Motion No. 1 to Deny Broad Priority Benefit to Its Earliest-filed Provisional Application | McDonnell Boehnen Hulbert & Berghoff LLP

On December 3rd, Senior Party Sigma-Aldrich filed its Substantive Preliminary Motion No. 1 in Interference No. 106,133 (which names the Broad Institute, Harvard University, and MIT (collectively, Broad) as Junior Party), asking the Patent Trial and Appeal Board to deny Broad benefit of its U.S. Provisional Application No. 61/736,527, filed…

Continue Reading Sigma-Aldrich Files Substantive Preliminary Motion No. 1 to Deny Broad Priority Benefit to Its Earliest-filed Provisional Application | McDonnell Boehnen Hulbert & Berghoff LLP

Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents

This article was originally published here Oncogene. 2021 Sep 20. doi: 10.1038/s41388-021-02021-y. Online ahead of print. ABSTRACT There has been accumulating evidence for the clinical benefit of chemoradiation therapy (CRT), whereas mechanisms in CRT-recurrent clones derived from the primary tumor are still elusive. Herein, we identified an aberrant BUB1B/BUBR1 expression…

Continue Reading Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents

2020 Heritable Human Genome Editing – Genômica

  editing methodologies. It is possible that continuing research may yield new methodologies that rapidly supersede the safety and efficacy of current editing approaches. Non-Heritable Genome Editing: The Use of Genome Editing in Somatic Cells One potential alternative to HHGE for the treatment of genetic dis- eases is somatic genome…

Continue Reading 2020 Heritable Human Genome Editing – Genômica

New Results from BabySeq, Pharmacogenomic Updates, New Products

September 1, 2021 | Harvard-Israel and Sema4-Avera launch precision medicine partnerships, Rice announces new Genetic Design and Engineering Center, Foundation Medicine partners with Epic, and Amgen and USC provide cryo-TEMs. Plus new products from BioIVT, BD.   Pluto Biosciences has launched its cloud-based, collaborative life sciences platform that leverages technology…

Continue Reading New Results from BabySeq, Pharmacogenomic Updates, New Products

Validation of gene editing efficiency with CRISPR-Cas9 system directly in rat zygotes using electroporation mediated delivery and embryo culture

doi: 10.1016/j.mex.2021.101419. eCollection 2021. Affiliations Expand Affiliations 1 Department of Biology, University of Alabama at Birmingham, Birmingham, AL, USA. 2 Cystic Fibrosis Research Center, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Free PMC article Item in Clipboard Anil K Challa et al….

Continue Reading Validation of gene editing efficiency with CRISPR-Cas9 system directly in rat zygotes using electroporation mediated delivery and embryo culture

CRISPR: Guide to gRNA design

Introduction to CRISPR in SnapGene Genome editing technology has been evolving for many years. The Holy Grail of genome engineering has always been to introduce a specific genetic change that affects only the genomic target and leaves no undesired changes in the DNA. The discovery and application of the bacterial…

Continue Reading CRISPR: Guide to gRNA design

CVC Files Opposition to ToolGen’s Substantive Preliminary Motion No. 2 | McDonnell Boehnen Hulbert & Berghoff LLP

In June, Senior Party ToolGen filed its Substantive Preliminary Motion No. 2 to deny Junior Party the University of California, Berkeley; the University of Vienna; and Emmanuelle Charpentier (collectively, “CVC”) priority benefit to its U.S. Provisional Application No. 61/757,640, filed January 28, 2013 (“Provisional 3”), pursuant to 37 C.F.R. §§…

Continue Reading CVC Files Opposition to ToolGen’s Substantive Preliminary Motion No. 2 | McDonnell Boehnen Hulbert & Berghoff LLP